Assessing Immunotherapy in Real Life: Have We Transferred the Increase in Overall Survival in Stage IV NSCLC from Trials to Clinical Practice?

被引：0
|
作者：
Sanchez Gonzalez, J. C. [1 ]
Nunez Garcia, B. [1 ]
Blanco Clemente, M. [1 ]
Calvo de Juan, V. [1 ]
Cantos Sanchez de Ibarguen, B. [1 ]
Mendez Garcia, M. [1 ]
Aguado Noya, R. [1 ]
Ruiz de Domingo, D. [1 ]
Gonzalez Sanchez, A. [1 ]
Provencio, M. [1 ]
机构：
[1] Hosp Univ Puerta Hierro, Majadahonda, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Immunotherapy; Advanced disease; Real World Data;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-06
引用
收藏
页码：S371 / S372
页数：2
相关论文
共 50 条
  • [1] Measuring the great objective: Have we transferred the increase in overall survival in stage IV non-small cell lung cancer from clinical trials to clinical practice?
    Sanchez, Juan Cristobal
    Garcia, Beatriz Nunez
    Blanco, Mariola
    Calvo, Virginia
    De Ibarguren, Blanca Cantos Sanchez
    Mendez, Miriam
    Aguado, Ramon
    Ramos-Vegue, Arturo Jose
    Royuela, Ana
    Provencio-Pulla, Mariano
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18734 - E18734
  • [2] Clinical predictors of survival in real world practice in stage IV melanoma
    Hu, Hsien-Pang
    Archer, Christine
    Yip, Desmond
    Peters, Geoffrey
    CANCER REPORTS, 2023, 6 (02)
  • [3] Clinical predictors of survival in real world practice in stage IV melanoma
    Hu, Hsien-Pang
    Archer, Christine
    Yip, Desmond
    Peters, Geoffrey
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 181 - 182
  • [4] Toxicities from immunotherapy: From clinical trials to real-world clinical practice
    Riveiro-Barciela, Mar
    Trallero-Araguas, Ernesto
    Martinez-Valle, Fernando
    MEDICINA CLINICA, 2020, 155 (12): : 541 - 547
  • [5] Recent changes in overall survival of real-life stage IV colorectal cancer patients.
    Hamers, Patricia
    Bos, Amanda C. R. K.
    May, Anne Maria
    Punt, Cornelis J. A.
    Koopman, Miriam
    Vink, Geraldine R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Evaluation of quality of life as an early surrogate of overall survival: An analysis from phase 3 immunotherapy trials
    Shahnam, Adel
    Nindra, Udit
    Hui, Rina
    Hopkins, Ashley M.
    Sorich, Michael J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 98 - 98
  • [7] Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC
    Fischer, J. R.
    Schulz, C.
    Laack, E.
    Wolff, T.
    Rueckert, A.
    Reck, M.
    Faehling, M.
    de Wit, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 209 - 209
  • [8] Impact of subsequent post-discontinuation immunotherapy on overall survival in patients with unresectable, stage III NSCLC from PACIFIC
    Ouwens, M.
    Darilay, A.
    Zhang, Y.
    Mukhopadhyay, P.
    Mann, H.
    Ryan, J.
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2019, 30 : 31 - 31
  • [9] Extrapolating data from clinical trials as we treat patients in real life
    Giordano, S.
    BREAST, 2019, 44 : S6 - S6
  • [10] Assessing quality of life in clinical research: From where have we come and where are we going?
    Wood-Dauphinee, S
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (04) : 355 - 363
12345